Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in July 2019 at the end of the 10-year period of market exclusivity.

On 17 February 2003, orphan designation (EU/3/03/132) was granted by the European Commission to Combino Pharm, S.L., Spain, for caffeine citrate for the treatment of primary apnoea of premature newborns. The sponsorship was transferred to Chiesi Farmaceutici S.P.A., Italy, in January 2007.

Caffeine citrate has been authorised in the EU as Peyona (previously Nymusa) since 2 July 2009.

Key facts

Active substance
Caffeine citrate
Medicine name
Disease / condition
Treatment of primary apnoea of premature newborns
Date of first decision
EU designation number

Sponsor's contact details

Chiesi Farmaceutici S.P.A.
Via Palermo 26/A
43100 Parma
Tel. +39 0521 279 793

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating